Novo Financial Statements From 2010 to 2024
NVO Stock | USD 128.40 0.35 0.27% |
Gross Profit 148.5 B | Profit Margin 0.3603 | Market Capitalization 574.2 B | Enterprise Value Revenue 2.4564 | Revenue 232.3 B |
Check Novo Nordisk financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novo main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.9 B, Interest Expense of 429.4 M or Selling General Administrative of 6.5 B, as well as many exotic indicators such as Short Term Coverage Ratios of 21.88, Price Earnings Ratio of 39.29 or Price To Sales Ratio of 14.16. Novo financial statements analysis is a perfect complement when working with Novo Nordisk Valuation or Volatility modules.
Novo | Select Account or Indicator |
Novo Nordisk Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novo Nordisk Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novo Nordisk Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Novo Fundamental Market Drivers
Forward Price Earnings | 38.1679 | |
Cash And Short Term Investments | 30.2 B |
Novo Upcoming Events
31st of January 2024 Upcoming Quarterly Report | View | |
2nd of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
31st of January 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
About Novo Nordisk Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Novo Nordisk income statement, its balance sheet, and the statement of cash flows. Novo Nordisk investors use historical funamental indicators, such as Novo Nordisk's revenue or net income, to determine how well the company is positioned to perform in the future. Although Novo Nordisk investors may use each financial statement separately, they are all related. The changes in Novo Nordisk's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novo Nordisk's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novo Nordisk Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novo Nordisk. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for 2024 | ||
Current Deferred Revenue | 123.7 B | 129.9 B | |
Total Revenue | 232.3 B | 243.9 B | |
Cost Of Revenue | 35.8 B | 37.6 B | |
Ebit Per Revenue | 0.44 | 0.46 |
Novo Nordisk Investors Sentiment
The influence of Novo Nordisk's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novo. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novo Nordisk's public news can be used to forecast risks associated with an investment in Novo. The trend in average sentiment can be used to explain how an investor holding Novo can time the market purely based on public headlines and social activities around Novo Nordisk AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novo Nordisk's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novo Nordisk's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novo Nordisk's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novo Nordisk.
Novo Nordisk Implied Volatility | 26.87 |
Novo Nordisk's implied volatility exposes the market's sentiment of Novo Nordisk AS stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Novo Nordisk's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Novo Nordisk stock will not fluctuate a lot when Novo Nordisk's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novo Nordisk in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novo Nordisk's short interest history, or implied volatility extrapolated from Novo Nordisk options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Novo Nordisk Correlation against competitors. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Commodity Directory Find actively traded commodities issued by global exchanges |
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.631 | Dividend Share 9.4 | Earnings Share 2.7 | Revenue Per Share 51.812 | Quarterly Revenue Growth 0.37 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.